P&T COMMUNITY
 
MediMedia Managed Markets
Our
Other
Journal
Managed Care magazine
P&T Community, The Online Resource for P&T Decision Makers
Login / Register
Join Us  Facebook  Twitter  Linked In

Breaking News

P&T TV

Where do new diabetes treatments fit in?

Randy Vogenberg, PhD: The differences among the latest diabetes medications are seen as less than dramatic, creating questions about the costs and benefits of the various new treatment options. Meanwhile, patient compliance remains a concern.

March 2014 interview

P&T Community

Update Your Registration Profile

Haven't received your weekly newsletters about the new features on PTcommunity.com? Check your newsletter status by clicking here. Scroll down to the question, 'Check here if you would like to receive our e-newsletter?' and choose 'Yes' or 'No.'

Having trouble with the site? Send an email.

Free App

MediMedia App IconManaged Care, and P&T are available for free on multiple mobile platforms and devices. For Apple and iOS devices, visit the Apple Store and download the free digital application for Managed Care and P&T.

Users of Android, Blackberry, Nook, and Kindle can view the mobile version on their respective devices by visiting these Web sites: Managed Care and P&T.

P&T Journal
for August 2014

Features

Letters to the Editor

In-House Drug Diversion by Hospital Personnel / Quality Measures at Compounding Facilities

Health Care & Law

Legal Risk Management Opportunities, Pharmacy Practice, and P&T Committees

Are Specialty Drug Prices Destroying Insurers and Hurting Consumers?

Irritable Bowel Syndrome: Current and Emerging Treatment Options

Meeting Highlights

European Hematology Association

Pipeline Plus

Ulcerative Colitis and Crohn’s Disease

Departments

Medication Errors

Oops, Sorry, Wrong Patient!

Prescription: Washington

HHS Alters Formulary Exception Policy for 2015

New Drugs/Drug News/New Medical Devices

Pharmaceutical Approval Update

Drug Forecast

Tedizolid Phosphate (Sivextro)

About P&T

Contacts:

Editorial: Sonja Sherritze, Editor
Advertising: Maureen Dwyer Liberti,
    Vice President, Group Publisher

Production: Mary Ellen Curry,
    Director of Production Services

Circulation: Jackie Ott, Circulation Manager

David B. Nash, MD, MBA, editor-in-chief of P&T, is Dean of the Jefferson School of Population Health, Philadelphia. From 1996 to 2003, he served as the first Associate Dean for Health Policy at Jefferson Medical College. In 2004, he was named Co-director of the Masters Program in Public Health at Jefferson.

View the rest of the Editorial Board here.

Call For Papers

P&T Journal is now accepting article submissions from its readers. We welcome a wide variety of manuscripts, including drug class reviews, disease state management reviews, pharmacoeconomic analyses, outcomes research evaluations, DUEs, P&T committee experiences, commentaries, book reviews, and letters to the editor. Please see our author guidelines below or contact the editor, Sonja Sherritze, via phone 267-685-2779 or email: ssherritze@medimedia.com.

Guidelines For Authors

Subscribe to P&T

Print Edition

Resources

Clinical Briefs

Pharmacy Policies/Procedures: Forms and guidelines

Cost Calculators: Exclusive online tools to evaluate your pharmacy costs

Links: A comprehensive map of web links to the world of managed care pharmacy

Formulary Kits

Abilify Maintena™
(aripiprazole) for extended-release injectable suspension

ADASUVE®
(loxapine) inhalation powder

BYDUREON® Pen
(exenatide extended-release for injectable suspension)

DUAVEE™
(Conjugated Estrogens/ Bazedoxifene)

ELIQUIS®
(apixaban) tablets

Please click for FULL PRESCRIBING INFORMATION including Boxed WARNINGS

Farxiga™
(dapagliflozin)

GRANIX™
(tbo-filgrastim) Injection

Injectafer®
(ferric carboxymaltose injection)

INVOKANA®
(canagliflozin)

JAKAFI®
(ruxolitinib)

Plegridy™
(peginterferon beta-1a)

Quillivant XR™
(methylphenidate HCl) for extended-release oral suspension, CII

Please click for FULL PRESCRIBING INFORMATION, including Boxed WARNING

Simponi®
(golimumab)

SIMPONI® ARIA™
(golimumab) for infusion

Recent Headlines